For those desiring to outshine the market, the strategic selection of individual stocks is paramount. Well-chosen stocks have the potential to substantially boost your wealth.
Transmedics Group Inc (NASDAQ: TMDX) closed the day trading at $124.00 down -8.96% from the previous closing price of $136.20. In other words, the price has decreased by -$8.96 from its previous closing price. On the day, 2.09 million shares were traded. TMDX stock price reached its highest trading level at $135.94 during the session, while it also had its lowest trading level at $123.0.
Ratios:
For a better understanding of TMDX, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 8.32 and its Current Ratio is at 9.10. In the meantime, Its Debt-to-Equity ratio is 1.95 whereas as Long-Term Debt/Eq ratio is at 1.94.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, JP Morgan on December 17, 2024, Downgraded its rating to Neutral and sets its target price to $75 from $116 previously.
Oppenheimer reiterated its Outperform rating for the stock on October 29, 2024, while the target price for the stock was revised from $200 to $125.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Jun 09 ’25 when Ranganath Anil P. sold 686 shares for $139.80 per share. The transaction valued at 95,903 led to the insider holds 13,955 shares of the business.
Basile Edward M sold 5,000 shares of TMDX for $632,250 on May 27 ’25. The Director now owns 2,866 shares after completing the transaction at $126.45 per share. On May 27 ’25, another insider, EDWARD BASILE, who serves as the Director of the company, bought 5,000 shares for $126.45 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, TMDX now has a Market Capitalization of 4195391232 and an Enterprise Value of 4403656704. As of this moment, Transmedics’s Price-to-Earnings (P/E) ratio for their current fiscal year is 91.14, and their Forward P/E ratio for the next fiscal year is 48.86. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 1.92. For the stock, the TTM Price-to-Sale (P/S) ratio is 8.59 while its Price-to-Book (P/B) ratio in mrq is 15.75. Its current Enterprise Value per Revenue stands at 9.02 whereas that against EBITDA is 59.42.
Stock Price History:
The Beta on a monthly basis for TMDX is 2.08, which has changed by -0.1388889 over the last 52 weeks, in comparison to a change of 0.092761636 over the same period for the S&P500. Over the past 52 weeks, TMDX has reached a high of $177.37, while it has fallen to a 52-week low of $55.00. The 50-Day Moving Average of the stock is 11.70%, while the 200-Day Moving Average is calculated to be 29.28%.
Shares Statistics:
Over the past 3-months, TMDX traded about 1.04M shares per day on average, while over the past 10 days, TMDX traded about 893730 shares per day. A total of 33.83M shares are outstanding, with a floating share count of 32.58M. Insiders hold about 3.71% of the company’s shares, while institutions hold 117.61% stake in the company. Shares short for TMDX as of 1748563200 were 8081988 with a Short Ratio of 7.80, compared to 1745971200 on 8796878. Therefore, it implies a Short% of Shares Outstanding of 8081988 and a Short% of Float of 41.27.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
The market rating for Transmedics Group Inc (TMDX) is a result of the insights provided by 6.0 analysts actively involved in the assessment.The consensus estimate for the next quarter is $0.3, with high estimates of $0.36 and low estimates of $0.26.
Analysts are recommending an EPS of between $1.93 and $1.7 for the fiscal current year, implying an average EPS of $1.79. EPS for the following year is $2.47, with 6.0 analysts recommending between $2.75 and $2.06.
Revenue Estimates
8 analysts predict $146.64M in revenue for the current quarter. It ranges from a high estimate of $150M to a low estimate of $144M. As of the current estimate, Transmedics Group Inc’s year-ago sales were $114.31MFor the next quarter, 8 analysts are estimating revenue of $140.81M. There is a high estimate of $145.3M for the next quarter, whereas the lowest estimate is $138.09M.
A total of 10 analysts have provided revenue estimates for TMDX’s current fiscal year. The highest revenue estimate was $585.4M, while the lowest revenue estimate was $576.27M, resulting in an average revenue estimate of $579.91M. In the same quarter a year ago, actual revenue was $441.54MBased on 9 analysts’ estimates, the company’s revenue will be $697.31M in the next fiscal year. The high estimate is $721.6M and the low estimate is $657M.
